AstraZeneca: filling a hole

A bit of good news at the pharma group; it needs more still

‘RouhaniCare’ set to boost Iran president

Tehran reaps benefits of making health a priority

Cipla buys US generics drugmakers

Indian pharma groups’ role in global supply chain grows

Short sellers target biotechs

Proportion of sector’s stock out on loan reaches 2015 high

Bayer to list Covestro in fourth quarter

Analysts point to €10bn-plus valuation for materials arm

FDA boost for AstraZeneca heart drug

Growth of Brilinta crucial to help offset decline in older products

Chef Jamie Oliver is urging the government to tax sugary drinks, after prevkously campaigning for healthier school meals
©Matt Russell

Oliver declares ‘absolute war’ on sugar

Sour note struck by doubts over transparency in own restaurants

This is an undated company photo of Amgen employee as he inspects samples of Kineret, a rheumatoid arthritis drug manufactured by Amgen Inc., at the company's manufacturing facility. Source:Amgen/WirePix/Via Bloomberg News.

Novartis sells first US bio copycat drug

Court victory opens way for rival to Amgen cancer medicine

Business Life. Doctor Gordon Sanghera, CEO of Oxford Nanopore.
©Andrew Fox

Oxford’s genes genie

British scientist behind pioneering DNA sequencer

Small-cap Week, August 29

SkyePharma, Tavistock, Oxaco, and MTI Wireless Edge featured

Abbott denies $25bn bid for St Jude

US pharma group had been preparing financing for a deal

Groups race to offload pension liabilities

New financial safety standards threaten to push up costs

Breakthrough in search for flu vaccine

Researchers carry out successful animal tests

Why we can exercise but not lose weight

Psychological factors behind a lack of success in shifting kilos

Cindy Whitehead, advocate of a passion elixir

QVC veteran has persuasive powers ordinary drug companies lack

Spire falls 14% after warning on NHS cuts

Private hospital operator blames decline in patient referrals as it downgrades forecasts

Valeant buys maker of ‘female Viagra’

Deal to buy Sprout for $1bn follows FDA approval of drug

Valeant and Sprout — neither hot nor bothered

A modest price for a mediocre drug

Kaz leaps 6% after currency devaluation

FTSE 100 at a seven-month low as metals and mining weaken

Officials call for ecigarette review

Report estimates product 95% less harmful than tobacco

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE